¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Complement C3-C5 Convertases, Alternative Pathway"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 11 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • complement inhibitor
    º¸Ã¼¾ïÁ¦Á¦, µµ¿òü¾ïÁ¦Á¦
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement profile
    º¸Ã¼Ãø¸é»ó
  • complement receptor
    º¸Ã¼¼ö¿ëü
  • complement system
    º¸Ã¼°è, µµ¿òü°èÅë
  • complement-dependent cytotoxicity
    º¸Ã¼ÀÇÁ¸¼¼Æ÷µ¶¼º
  • complement-fixing antibody
    º¸Ã¼°áÇÕÇ×ü, µµ¿òü°áÇÕÇ×ü
  • complement-induced
    º¸Ã¼À¯µµ-
  • complement-mediated
    º¸Ã¼¸Å°³-
  • complement-mediated cytotoxicity
    º¸Ã¼¸Å°³¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºº¸Ã¼
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 12 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • complement splitting
    µµ¿òüºÐ¿­, º¸Ã¼ºÐ¿­
  • complement system
    µµ¿òü°èÅë, º¸Ã¼°èÅë
  • complement typing
    º¸Ã¼Çüº°°Ë»ç
  • complement deficient state
    µµ¿òü°áÇÌ»óÅÂ, º¸Ã¼°áÇÌ»óÅÂ
  • complement fixation reaction
    º¸Ã¼°áÇÕ¹ÝÀÀ, µµ¿òü°áÇÕ¹ÝÀÀ
  • complement fixation test
    µµ¿òü°áÇÕ½ÃÇè, º¸Ã¼°áÇÕ½ÃÇè
  • complement fixation unit
    º¸Ã¼°áÇÕ´ÜÀ§
  • complement fixation inhibition test
    º¸Ã¼°áÇÕ¾ïÁ¦½ÃÇè
  • complement mediated lysis
    º¸Ã¼¸Å°³¿ëÇØ, µµ¿òü¸Å°³¿ëÇØ
  • complement-dependent cytotoxicity
    µµ¿òüÀÇÁ¸¼¼Æ÷µ¶¼º
  • complement-mediated cytotoxicity
    µµ¿òü°ü·Ã¼¼Æ÷µ¶¼º
  • dominant complement
    ¿ì¼ºµµ¿òü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • mesolimbic-mesocortical pathway
    Áߺ¯¿¬°è-ÁßÇÇÁú°æ·Î(ñéÜ«æÞÍ£-ñéù«òõÌèÖØ)
  • metabolic pathway
    ´ë»ç°æ·Î.
  • neurohumoral pathway
    ½Å°æ¾×¼º °æ·Î(~ÌèÖØ).
  • nigrostriatal pathway
  • oculomotor pathway
    ¾È±¸¿îµ¿½Å°æ·Î(äÑÏ¹ê¡ ÔÑãêÌèÖØ).
  • optic pathway
    ½Ã·Î.
  • optic pathway
    ½Ã½Å°æ·Î.
  • pain pathway
    Åë°¢Àü´Þ·Î(÷ÔÊÆîîÓ¹ÖØ).
  • pancreas,protein secertion pathway
    ´Ü¹éÁúºÐºñ°æ·Î(Ó±ÛÜòõÝÂÝôÌèÖØ)
  • parallel pathway
    (°¨°¢Á¤º¸Ã³¸®ÀÇ)ÆòÇà°æ·Î
  • pathway
    °æ·Î(ÌèÖØ).
  • pentose phosphate pathway
    ¿Àź´ç ÀλêÈ­ ¹ÝÀÀ
  • phosphogluconate oxidative pathway
    ±Û·çÄÜ»ê»êÈ­°æ·Î, ÀÎ´ç¿ø»êÈ­°æ·Î(ìÝÓØ ê«ß«ûùÌèÖØ).
  • proximal common pathway
    ±ÙÀ§°øÅë°æ·Î.
  • pyruvate pathway
    ÇÇ·çºê»ê¿°´ë»ç°æ·Î(¡­ß«ç¤ÓÛÞóÌèÖØ).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • glycerate pathway
    ±Û¸®¼¼¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • glycolytic pathway
    ´çºÐÇØ °æ·Î(ÓØÝÂú°ÌèÖØ)
  • hexose diphosphate pathway
    ÀÌÀλê(ì£×òß«) Çí¼Ò½º °æ·Î (ÌèÖØ)
  • hexose monophosphate oxidative pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º »êÈ­°æ·Î (ß«ûùÌèÖØ)
  • hexose monophosphate pathway
    ÀÏÀλê(ìé×òß«) Çí¼Ò½º °æ·Î(ÌèÖØ)
  • hoxose phosphoketolase pathway
    Çí¼Ò½º Æ÷½ºÆ÷ŰÅç·¹À̽º °æ·Î(ÌèÖØ)
  • intrinsic pathway
    ³»ÀÎ °æ·Î(Ò®ì×ÌèÖØ)
  • -ketoadipate pathway
    -ÄÉÅ侯µðÇÁ»ê(ß«)°æ·Î(ÌèÖØ)
  • -ketoglutrate pathway
    -ÄÉÅ䱸¸£Å¸¸£»ê(ß«) °æ·Î(ÌèÖØ)
  • layered metabolic pathway
    Ãþ´ë»ç°æ·Î(öµÓÛÞóÌèÖØ)
  • linear metabolic pathway
    ¼±Çü ´ë»ç°æ·Î(àÊû¡ÓÛÞóÌèÖØ)
  • long patch pathway
    ÀåÆí °æ·Î(íþø¹ÌèÖØ)
  • mandelate pathway
    ¸¸µ¨»ê(ß«) °æ·Î(ÌèÖØ)
  • metabolic pathway
    ´ë»ç °æ·Î(ÓÛÞóÌèÖØ)
  • oxaloacetate pathway
    ¿Á»ì¾Æ¼¼Æ®»ê(ß«) °æ·Î(ÌèÖØ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
ADS acute death syndrome; acute diarrheal syndrome; Alcohol Dependence Scale; alternative delivery syste...
AFS acquired or adult Fanconi syndrome; alternative financing system; American Fertility Society; antifi...
AIS/MR Alternative Intermediate Services for the Mentally Retarded
ALC absolute lymphocyte count; acute lethal catatonia; aided living center; Alternative Lifestyle Checkl...
ECVAM European Centre for the Validation of Alternative Methods
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
EPI Extrinsic Pathway Inhibitor
HMP Hexose monophosphate pathway
rTFPI Recombinant tissue factor pathway inhibitor
TFPI TF pathway inhibitor
TFPI Tissue Factor Pathway Inhibitor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • intrinsic pathway
    ³»ºÎ °æ·Î, ³»Àμº °æ·Î
  • medial pathway
    ³»Ãø °æ·Î
  • meridian pathway
    °æ¶ô, °æ·Î
    µ¿¾ç ÀÇÇп¡¼­ ¹°¸® ¿ä¹ý, ƯÈ÷ ħ±¸ Ä¡·áÀÇ À̷Рü°è·Î¼­ Áß¿ä½ÃµÇ´Â °æÇ÷
  • metabolic pathway
    ´ë»ç °æ·Î
  • neural pathway
    ½Å°æ °æ·Î, ½Å°æ Åë·Î
    ÀÓÆÞ½º°¡ Àü´ÞµÇ´Â ½Å°æ ±¸Á¶¹°.
  • orbiting pathway
    ±Ëµµ
  • paleothalamic pathway
    °í½Ã»ó Àü´Þ·Î
  • paramedian pathway
    Á¤Áß¹æ °æ·Î
  • pathway
    °æ·Î, Àüµµ·Î
    Àüµµ·Î¶ó°í ÇÏ´Â °ÍÀº ³ú ¶Ç´Â ô¼ö¿¡ À־ÀÇ ÁßÃß¿Í ½Åü ¸»Ãʸ¦ ¿¬°áÇÏ´Â Åõ»ç ½Å°æ·Î¸¦ ¸»ÇÏ´Â °ÍÀ¸·Î Åõ»ç ½Å°æ·Î´Â ½Ä¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °Í°ú µ¿¹° ½Å°æ°è¿¡ ¼ÓÇÏ´Â °ÍÀ¸·Î ´ëº°ÇÒ ¼ö ÀÖ´Ù. ±×ÀÇ ¾î´À °Í¿¡µµ »óÇ༺
  • pentose hosphate pathway

    pentose nucleic acid (ÆæÅ佺 ÇÙ»ê

  • salvage pathway
    ±¸Á¦ °æ·Î, ÀçÀÌ¿ë °æ·Î
    ±âÁ¸ ¹°ÁúÀ» »ç¿ëÇØ ÇÕ¼ºÇÏ´Â °æ·Î.
  • secondary pathway
    ÀÌÂ÷ °æ·Î
  • sensory pathway
    °¨°¢·Î
  • somatosensory conduction pathway
    ü°¨°¢ Àüµµ °æ·Î
  • spinal pathway
    ô¼ö °æ·Î
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
hexose monphosphate pathway A metabolic pathway present in a wide range of prokaryotic and eukaryotic microorganisms as well as in plants and animals, it involves the oxidative decarboxylation of glucose-6-phosphate, via 6 phosphogluconate, to ribulose 5-phosphate, followed by a series of reversible, non-oxidative interconversions whereby hexose and triose phosphates are formed from pentose phosphates.
(09 Oct 1997)
HSK pathway <biochemistry> Metabolic pathway responsible for primary carbon dioxide fixation in C4 plant photosynthesis.
The enzymes that are found in mesophyll chloroplasts include PEP carboxylase, that adds carbon dioxide to phosphoenolpyruvate to give the 4 carbon compound, oxaloacetate. Four carbon compounds are transferred to bundle sheath chloroplasts, where the carbon dioxide is liberated and re fixed by the Calvin Benson cycle.
The Hatch Slack Kortshak pathway permits efficient photosynthesis under conditions of high light intensity and low carbon dioxide concentration, avoiding the nonproductive effects of photorespiration.
Acronym: HSK pathway
(15 Nov 1997)
shikimic acid pathway <biochemistry> Metabolic pathway in plants and microorganisms, by which the aromatic amino acids (phenylalanine, tyrosine and tryptophan) are formed from phosphoenolpyruvate and erythrose 4 phosphate via shikimic acid. The aromatic amino acids in turn serve as precursors for the formation of lignin and other phenolic compounds in plants. Inhibitors of this pathway are used as herbicides.
(18 Nov 1997)
sorbitol pathway A pathway responsible for d-fructose formation from sorbitol; increases in activity as the glucose concentration rises in diabetes.
Synonym: polyol pathway.
(05 Mar 2000)
neural pathway <anatomy> Neural tracts connecting one part of the nervous system with another.
(12 Dec 1998)
de novo pathway <biochemistry> A pathway for synthesising a biomolecule from simple precursor molecules.
Compare: salvage pathway.
(12 Jan 1998)
DNA repair pathway The sequence of steps in the repair of DNA. Each step is governed by an enzyme.
(12 Dec 1998)
drug development pathway The various procedures and studies that must be undertaken to satisfy Food and Drug Administration requirements for drug approval and marketing.
(14 Nov 1997)
intrinsic pathway <haematology> Initiation of blood clotting as a result of factors released from damaged tissue, as opposed to contact with a foreign surface (the intrinsic pathway).
Tissue thromboplastin (Factor III) in conjunction with Factor VII proconvertin) will activate Factor X that, once activated, converts prothrombin to thrombin.
(27 Jun 1999)
Embden-Meyerhof-Parnas pathway A pathway that degrades glucose to pyruvate, the six-carbon stage converts glucose to fructose-1,6-bisphosphate, and the three-carbon stage produces ATP while changing glyceraldehyde-3-phosphate to pyruvate.
Compare: Entner-Doudoroff pathway.
(09 Oct 1997)
Embden-Meyerhof pathway The main pathway for anerobic degradation of carbohydrate. Starch or glycogen is hydrolysed to glucose 1 phosphate and then through a series of intermediates, yielding two ATP molecules per glucose and producing either pyruvate which feeds into the tricarboxylic acid cycle) or lactate.
(18 Nov 1997)
Entner-Douderoff pathway A degradative pathway for carbohydrates in certain microorganisms (e.g., Pseudomonas sp.) that lack hexokinase, phosphofructokinase, and glyceraldehyde-3-phosphate dehydrogenase.
(05 Mar 2000)
Entner-Doudoroff pathway <biochemistry> A pathway that converts glucose to pyruvate and glyceraldehyde-3 phosphate by producing 6-phosphogluconate and then dehydrating it.
(09 Oct 1997)
extrinsic pathway <haematology> Initiation of blood clotting as a result of factors released from damaged tissue, as opposed to contact with a foreign surface (the intrinsic pathway).
Tissue thromboplastin (Factor III) in conjunction with Factor VII proconvertin) will activate Factor X that, once activated, converts prothrombin to thrombin.
(27 Jun 1999)
4-aminobutyrate pathway The pathway that ultimately converts 4-aminobutyrate to succinate; succinate is then converted to alpha-ketoglutarate, via the tricarboxylic acid cycle, which is then acted upon by glutamate dehydrogenase; glutamate is then decarboxylated to reform 4-aminobutyrate; an important pathway for those cells which make this neuroactive molecule.
Synonym: GABA pathway.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á